{"filings":[{"id":94884,"accession_number":"0001193125-26-213472","cik":1709941,"company_name":"BioAge Labs, Inc.","ticker":"BIOA","form_type":"8-K","filed_at":"2026-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioAge Labs Q1 net loss $22.3M; positive Phase 1 data for BGE-102 NLRP3 inhibitor","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $22.3M ($0.52 diluted EPS) vs $12.9M ($0.36) in Q1 2025; R&D spend rose to $20.4M.","Positive Phase 1 data for oral NLRP3 inhibitor BGE-102: median hsCRP reduction 86%, 87-93% reached normalized hsCRP <2 mg/L.","Ph2 dose-ranging trial in CVD risk and Ph1b/2a in diabetic macular edema both planned to start mid-2026.","Cash, equivalents & securities $384.9M as of Mar 31, 2026; funded through 2029.","Completed upsized follow-on offering for $132.3M in gross proceeds in early 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":2772000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":745472414.1823009,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107578,"accession_number":"0001193125-26-120864","cik":1709941,"company_name":"BioAge Labs, Inc.","ticker":"BIOA","form_type":"8-K","filed_at":"2026-03-24T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"BioAge reports FY2025 net loss $80.6M; positive BGE-102 Phase 1 data; $132M offering","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Positive interim Phase 1 data for BGE-102: 86% median hsCRP reduction, 93% of obese participants reached <2 mg/L.","Phase 2a cardiovascular trial planned 1H 2026; ophthalmology expansion with DME trial mid-2026.","Completed $132.3M follow-on offering in Feb 2026; cash $285.1M at Dec 31, 2025, sufficient through 2029.","FY2025: collaboration revenue $9.0M (vs $0); net loss $80.6M ($2.24/share) vs $71.1M ($6.63/share) in 2024.","APJ agonist programs advancing; IND filing expected by end of 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":745472414.1823009,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107577,"accession_number":"0001193125-26-019536","cik":1709941,"company_name":"BioAge Labs, Inc.","ticker":"BIOA","form_type":"8-K","filed_at":"2026-01-22T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"BioAge Labs prices upsized $115M public offering of 5.9M shares at $19.50/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["5,897,435 shares offered at $19.50/share; gross proceeds ~$115M, net ~$107.6M.","Underwriters have 30-day option to purchase up to 884,615 additional shares.","Proceeds to fund BGE-102, NLRP3, and APJ programs, plus working capital and debt reduction.","Goldman Sachs, Piper Sandler, and Citigroup are joint book-running managers.","Offering expected to close on January 23, 2026, subject to customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":745472414.1823009,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107576,"accession_number":"0001193125-26-016046","cik":1709941,"company_name":"BioAge Labs, Inc.","ticker":"BIOA","form_type":"8-K","filed_at":"2026-01-20T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"BioAge Labs expands BGE-102 into diabetic macular edema; Phase 1b/2a trial planned mid-2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Plans to initiate Phase 1b/2a proof-of-concept trial in DME in mid-2026; results expected mid-2027.","Preclinical DME model: oral BGE-102 achieved near-complete protection from vascular leakage and up to 90% preservation of microvascular integrity.","BGE-102 ongoing Phase 1 shows favorable tolerability and robust reductions in hsCRP, IL-6, and IL-1β.","Additional milestones: 1H2026 complete Phase 1, start CV risk Phase 2a; 2H2026 CV risk data.","Cites growing clinical evidence for targeting inflammation in retinal diseases, including intravitreal IL-6 inhibitors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":745472414.1823009,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107575,"accession_number":"0001193125-26-009911","cik":1709941,"company_name":"BioAge Labs, Inc.","ticker":"BIOA","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"BioAge positive Phase 1 data for BGE-102: 86% hsCRP reduction, 93% normalized","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BGE-102 achieved 86% median hsCRP reduction at Day 14 in obese patients with elevated baseline hsCRP; 93% reached <2 mg/L.","Significant reductions in IL-6 (44%) and fibrinogen (30%) observed, indicating downstream inflammatory cascade suppression.","BGE-102 well tolerated with no dose-limiting toxicities; favorable safety profile.","Phase 1 completion and Phase 2a initiation in obese patients with CV risk factors expected in 1H 2026.","Patent issued covering additional composition of matter and novel NLRP3 binding site."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":745472414.1823009,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123935,"accession_number":"0001193125-25-307541","cik":1709941,"company_name":"BioAge Labs, Inc.","ticker":"BIOA","form_type":"8-K","filed_at":"2025-12-04T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"BioAge reports positive Phase 1 interim data for NLRP3 inhibitor BGE-102; 90-98% IL-1β suppression","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BGE-102 well-tolerated across all doses (SAD: 10-120 mg; MAD: 60-120 mg); AEs mild/moderate, all resolved.","90-98% suppression of IL-1β at Day 14; doses ≥60 mg exceeded IC90 in CSF, demonstrating high brain penetration.","Phase 1 expanded to MAD cohorts in obese participants with elevated hsCRP; data expected 1H26.","Phase 2a proof-of-concept planned for 1H26 (100 patients, 12 weeks, primary endpoint % hsCRP change); data readout 2H26.","Pharmacokinetics support once-daily oral dosing; dose proportionality observed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":745472414.1823009,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123934,"accession_number":"0001193125-25-269986","cik":1709941,"company_name":"BioAge Labs, Inc.","ticker":"BIOA","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioAge Q3 net loss $20.2M; first participant dosed in BGE-102 Phase 1 trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $20.2M ($0.56 EPS) vs $23.4M ($6.70) in Q3 2024; collaboration revenue $2.1M from Novartis deal.","Cash, equivalents, and marketable securities $295.9M as of Sept 30, 2025, expected to fund operations through 2029.","First participant dosed in Phase 1 trial of oral NLRP3 inhibitor BGE-102; initial SAD data expected by year-end 2025.","Oral and parenteral APJ agonist programs on track for IND submissions in 2026; U.S. provisional patent filed May 2025.","Partnerships with Novartis and Lilly advancing as expected."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":5917000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":745472414.1823009,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140599,"accession_number":"0000950170-25-104151","cik":1709941,"company_name":"BioAge Labs, Inc.","ticker":"BIOA","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioAge Labs Q2 net loss $21.6M, cash $313.4M; BGE-102 Phase 1 on track for 2H 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $21.6M ($0.60/share) vs $13.6M loss in Q2 2024; R&D expenses rose to $19.8M.","Cash and marketable securities $313.4M as of June 30, 2025; runway through 2029.","BGE-102 IND-enabling completed; Phase 1 SAD/MAD starts 2H 2025 with data by year-end.","Option agreement for APJ agonist nanobody with >10x apelin potency; oral APJ patent filed.","Launched HUNT Biobank collaboration to profile 17,000+ samples for aging biology."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.96,"consensus_revenue_estimate":null,"consensus_revenue_actual":3863000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":745472414.1823009,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158309,"accession_number":"0000950170-25-083746","cik":1709941,"company_name":"BioAge Labs, Inc.","ticker":"BIOA","form_type":"8-K","filed_at":"2025-06-09T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"BioAge Labs shareholders elect three Class I directors; ratify KPMG as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Class I directors Kristen Fortney, Eric Morgen, Vijay Pande to three-year terms expiring at 2028 annual meeting.","Fortney received 17.3M for, 2.1M withheld; Morgen 17.2M for, 2.2M withheld; Pande 17.2M for, 2.2M withheld.","Ratified KPMG LLP as independent auditor for FY 2025: 25.4M for, 55K against, 6.8K abstentions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":745472414.1823009,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158308,"accession_number":"0000950170-25-081409","cik":1709941,"company_name":"BioAge Labs, Inc.","ticker":"BIOA","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"BioAge provides NLRP3 & APJ program timeline updates in corporate presentation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["NLRP3 program: IND submission and Phase 1 SAD/MAD initiation planned for mid-2025; initial SAD data expected by end of 2025.","Full Phase 1 SAD/MAD data for NLRP3 program anticipated in mid-2026.","Obesity proof-of-concept data for NLRP3 program expected in second half of 2026.","APJ agonist program (oral and parenteral) expects IND submission by end of 2026.","Company continues to advance both programs, with no financial guidance or data results provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":745472414.1823009,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158307,"accession_number":"0000950170-25-064547","cik":1709941,"company_name":"BioAge Labs, Inc.","ticker":"BIOA","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioAge Labs Q1 net loss $12.9M; cash $335.1M; BGE-102 Phase 1 data expected 2H25","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $12.9M ($0.36 diluted EPS) vs $13.0M loss in Q1 2024; no revenue reported.","R&D expenses $11.1M up from $9.3M YoY on IND-enabling work for BGE-102.","G&A expenses $6.8M up from $3.5M YoY driven by stock-based compensation and D&O insurance.","Cash, equivalents, and marketable securities $335.1M as of March 31, 2025; funds operations through 2029.","Lead candidate BGE-102 (NLRP3 inhibitor) enters IND-enabling studies; initial Phase 1 data anticipated 2H25."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":1451000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":745472414.1823009,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176685,"accession_number":"0000950170-25-042747","cik":1709941,"company_name":"BioAge Labs, Inc.","ticker":"BIOA","form_type":"8-K","filed_at":"2025-03-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioAge Labs FY2024 net loss $71.1M; advances NLRP3 inhibitor BGE-102; discontinues azelaprag","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $71.1M ($6.63/share) for FY2024; cash $354.3M expected to fund operations through 2029.","Discontinued azelaprag Phase 2 STRIDES trial due to unexpected liver transaminitis; continuing next-generation APJ agonists.","Nominated BGE-102, an oral brain-penetrant NLRP3 inhibitor; Phase 1 SAD data expected 2H25, MAD data 1H26.","New collaborations: Novartis (up to $20M upfront, $530M milestones) and Lilly (antibody discovery for metabolic aging targets).","R&D expenses $59.0M (up 74% YoY); G&A $19.2M (up 32% YoY)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":745472414.1823009,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193524,"accession_number":"0000950170-24-123437","cik":1709941,"company_name":"BioAge Labs, Inc.","ticker":"BIOA","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioAge Labs Q3 net loss $23.4M; IPO proceeds extend cash runway into 2029","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $23.4M ($6.70/share) vs $14.6M ($8.74/share) in Q3 2023; R&D spend rose to $20.0M on Phase 2 STRIDES trial.","Cash and cash equivalents at Sept. 30, 2024: $334.5M, with additional $27.6M from underwriter option in Oct. 2024.","IPO and concurrent private placement yielded ~$189.5M net, plus $27.6M from underwriter option; cash sufficient into 2029.","Phase 2 STRIDES trial of azelaprag + tirzepatide for obesity dosed first patient; top-line results expected Q3 2025.","Appointed former GSK CEO Jean-Pierre Garnier as Board Chair, succeeding James Healy who remains a director."],"consensus_eps_estimate":null,"consensus_eps_actual":-21.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":745472414.1823009,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209830,"accession_number":"0001193125-24-227949","cik":1709941,"company_name":"BioAge Labs, Inc.","ticker":"BIOA","form_type":"8-K","filed_at":"2024-09-27T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"BioAge Labs sells 588,888 shares to Sofinnova at $18 in private placement concurrent with IPO","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Private placement of 588,888 shares to existing stockholder Sofinnova at IPO price of $18.00/share, raising $10.6 million.","Placement agents Goldman Sachs, Morgan Stanley, Jefferies, Citigroup received 7.0% fee on total purchase price.","Shares unregistered, issued under Section 4(a)(2) to an institutional accredited investor; registration rights after one year if not saleable under Rule 144.","Closing occurred on September 27, 2024, concurrently with the IPO closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":745472414.1823009,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}